Biogen (BIIB) Revenue — Quarter Ended Mar 31, 2023
Revenue for the quarter declined compared with both the prior quarter and the same quarter last year. The decrease continues a pattern of year-over-year contraction observed in recent periods.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue for the quarter declined compared with both the prior quarter and the same quarter last year. The decrease continues a pattern of year-over-year contraction observed in recent periods.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
-3.2%
Change from the immediately preceding quarter.
Year-over-year
-4.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$10.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $2.6B | -3.9% |
| Sep 30, 2022 | $2.5B | -9.7% |
| Dec 31, 2022 | $2.5B | -6.9% |
| Mar 31, 2023 | $2.5B | -4.9% |
Revenue performance
The reported revenue moved lower from the immediately preceding quarter. It also fell relative to the same quarter one year earlier.
Quarterly comparison
Compared with the prior quarter, revenue decreased. Versus the same quarter a year ago, revenue also decreased.
What to watch
The filing context mentions recent regulatory developments for LEQEMBI, including FDA actions and international submissions, which may affect future revenue.